Literature DB >> 8167491

Long term acid suppressing treatment in general practice.

S D Ryder1, S O'Reilly, R J Miller, J Ross, M R Jacyna, A J Levi.   

Abstract

OBJECTIVE: To determine the current practice in selected general practices for prescribing long term (> 6 months) treatment to suppress gastric acid secretion.
SETTING: Seven general practices in the Harrow area that always or usually refer to Northwick Park Hospital.
SUBJECTS: 60,148 patients on lists of the general practices.
DESIGN: Identification of patients receiving long term treatment through repeat prescribing data, followed by a manual and computer survey of patients' notes for indications and investigations. Patient compliance and views on treatment were sought by a postal questionnaire. MAIN OUTCOME MEASURES: Indications for treatment, treatment given, investigations undertaken before and during treatment.
RESULTS: 492 patients (0.82% of the population) were taking long term acid suppressing treatment. The most common diagnosis was duodenal ulcer disease (183 (37%) of all patients); oesophageal disease (118 (24%)) was also common. 93 patients (19%) were treated for abdominal pain where no diagnosis had been reached or who had only a diagnosis of gastritis on endoscopy. Ranitidine was prescribed in 394 (80%) patients. 298 (74%) patients found treatment helpful, but 108 (27%) had a poor understanding of their diagnosis. 317 patients (78%) took their drug as prescribed. 37 patients were also taking prescribed non-steroidal anti-inflammatory drugs and an additional 43 patients took regular aspirin or ibuprofen without prescription.
CONCLUSIONS: Long term acid suppressing treatment is common, and a substantial number of patients are taking these drugs long term without a diagnosis having been reached. It is hoped that protocols for investigation and treatment will improve these figures. Patients need to be better informed about their disease and the possible adverse effects of taking non-steroidal anti-inflammatory drugs in acid related upper gastrointestinal disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167491      PMCID: PMC2539987          DOI: 10.1136/bmj.308.6932.827

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

1.  Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori.

Authors:  M R Millar; J Pike
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Cimetidine prescribing patterns in a military community hospital.

Authors:  J W Saultz
Journal:  Mil Med       Date:  1985-06       Impact factor: 1.437

3.  Utilization of nonsteroidal antiinflammatory drugs.

Authors:  C Baum; D L Kennedy; M B Forbes
Journal:  Arthritis Rheum       Date:  1985-06

4.  [Uncharacteristic dyspepsia in general practice. A controlled trial with an antacid (Alminox)].

Authors:  N Nørrelund; A Helles; M Schmiegelow
Journal:  Ugeskr Laeger       Date:  1980-06-30

5.  A survey of cimetidine prescribing.

Authors:  A E Cocco; D V Cocco
Journal:  N Engl J Med       Date:  1981-05-21       Impact factor: 91.245

6.  Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.

Authors:  K Somerville; G Faulkner; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

7.  A multicenter study of ranitidine treatment of duodenal ulcers in the United States.

Authors:  B I Hirschowitz; M M Berenson; J M Berkowitz; P Bright-Asare; V A DeLuca; F N Eshelman; R G Font; J W Griffin; R A Kozarek; R S McCray
Journal:  J Clin Gastroenterol       Date:  1986-06       Impact factor: 3.062

8.  Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia.

Authors:  N J Talley; D McNeil; A Hayden; D W Piper
Journal:  Gastroenterology       Date:  1986-07       Impact factor: 22.682

9.  Cimetidine responders in non-ulcer dyspepsia.

Authors:  T Johannessen; U Fjøsne; P M Kleveland; T Halvorsen; P Kristensen; I Løge; P E Hafstad; P Sandbakken; H Petersen
Journal:  Scand J Gastroenterol       Date:  1988-04       Impact factor: 2.423

10.  H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.

Authors:  J W Freston
Journal:  Am J Gastroenterol       Date:  1987-12       Impact factor: 10.864

View more
  23 in total

1.  Reducing dyspepsia costs in the community.

Authors:  A Duggan; J Westbrook
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

2.  Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice.

Authors:  Raffaella Scagliarini; Elena Magnani; Antonino Praticò; Renato Bocchini; Paola Sambo; Paolo Pazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Inappropriate prescribing of proton pump inhibitors in primary care.

Authors:  Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

4.  The science of perpetual change.

Authors:  A Haines
Journal:  Br J Gen Pract       Date:  1996-02       Impact factor: 5.386

5.  Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Studies'assumptions are removed from clinical practice.

Authors:  I Trimble; C Derrett
Journal:  BMJ       Date:  1996-09-07

6.  Examining the value of eradication therapy for H. pylori.

Authors:  B Delaney; F D Hobbs; J E Kenkre; M Rowsby
Journal:  Br J Gen Pract       Date:  1996-08       Impact factor: 5.386

7.  Who controls repeats?

Authors:  A G Zermansky
Journal:  Br J Gen Pract       Date:  1996-11       Impact factor: 5.386

8.  Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.

Authors:  M Tavakoli; A T Prach; M Malek; D Hopwood; B W Senior; F E Murray
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 9.  Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1995-09       Impact factor: 5.386

10.  Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care.

Authors:  S Verma; M H Giaffer
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.